CEO of Dalrada Financial Corporation Subsidiary, Genefic, Inc. Discusses Revenue Drivers and Growth in New Interview
Genefic, Inc., a subsidiary of Dalrada Financial (OTCQB:DFCO), has released a new video interview featuring CEO Dan Riley. The interview highlights Genefic's significant revenue growth and success in the specialty pharmacy space since its launch in October 2023. Riley discusses the company's impressive quarterly performance, with revenue jumping from $4 million to $8 million in consecutive quarters.
The interview also covers Genefic's expansion strategy, which includes two licensed diagnostic laboratories, a 50-state licensed specialty pharmacy, and a recently-acquired infusion pharmacy in the New Orleans area. Riley emphasizes the company's goal to become a one-stop shop for all pharmacy services and verticals, potentially entering the compounding pharmacy market as well.
Genefic, Inc., una filiale di Dalrada Financial (OTCQB:DFCO), ha rilasciato una nuova intervista video con il CEO Dan Riley. L'intervista evidenzia la significativa crescita del fatturato di Genefic e il successo nel settore delle farmacie specializzate dal suo lancio nell'ottobre 2023. Riley discute le impressionanti performance trimestrali dell'azienda, con un fatturato che è passato da 4 milioni a 8 milioni di dollari in trimestri consecutivi.
L'intervista affronta anche la strategia di espansione di Genefic, che include due laboratori diagnostici autorizzati, una farmacia specializzata autorizzata in tutti i 50 stati e una farmacia di infusione recentemente acquisita nell'area di New Orleans. Riley sottolinea l'obiettivo dell'azienda di diventare un unico punto di riferimento per tutti i servizi e settori farmaceutici, con la possibilità di entrare anche nel mercato delle farmacie di preparazione.
Genefic, Inc., una subsidiaria de Dalrada Financial (OTCQB:DFCO), ha lanzado una nueva entrevista en video con el CEO Dan Riley. La entrevista destaca el significativo crecimiento de ingresos de Genefic y el éxito en el espacio de la farmacia especializada desde su lanzamiento en octubre de 2023. Riley discute el impresionante desempeño trimestral de la compañía, con ingresos que saltaron de $4 millones a $8 millones en trimestres consecutivos.
La entrevista también cubre la estrategia de expansión de Genefic, que incluye dos laboratorios diagnósticos con licencia, una farmacia especializada con licencia en los 50 estados y una farmacia de infusión recientemente adquirida en el área de Nueva Orleans. Riley enfatiza el objetivo de la empresa de convertirse en una tienda integral para todos los servicios y verticales de farmacia, con la posibilidad de entrar también en el mercado de farmacias de preparación.
Genefic, Inc.는 Dalrada Financial (OTCQB:DFCO)의 자회사로, CEO Dan Riley와의 새로운 비디오 인터뷰를 공개했습니다. 인터뷰에서는 Genefic의 상당한 매출 성장과 2023년 10월 출시 이후 전문 약국 분야에서의 성공을 강조합니다. Riley는 회사의 인상적인 분기 실적을 논의하며, 매출이 400만 달러에서 800만 달러로 증가했다고 전합니다.
인터뷰는 또한 Genefic의 확장 전략을 다루고 있으며, 여기에는 두 개의 면허를 가진 진단 실험실, 50개 주 면허를 가진 전문 약국 및 최근에 인수한 뉴올리언스 지역의 주사 약국이 포함됩니다. Riley는 회사의 목표가 모든 약국 서비스와 분야를 위한 원스톱 샵이 되는 것이라고 강조하며, 복제 약국 시장에도 진입할 가능성을 암시합니다.
Genefic, Inc., une filiale de Dalrada Financial (OTCQB:DFCO), a publié une nouvelle interview vidéo mettant en vedette le CEO Dan Riley. L'interview met en lumière la croissance significative des revenus de Genefic et le succès dans le domaine des pharmacies spécialisées depuis son lancement en octobre 2023. Riley discute de la performance trimestrielle impressionnante de l'entreprise, avec des revenus passant de 4 millions à 8 millions de dollars au cours de trimestres consécutifs.
L'interview aborde également la stratégie d'expansion de Genefic, qui comprend deux laboratoires diagnostiques agréés, une pharmacie spécialisée agréée dans les 50 états, et une pharmacie d'infusion récemment acquise dans la région de La Nouvelle-Orléans. Riley souligne l'objectif de l'entreprise de devenir un guichet unique pour tous les services et secteurs pharmaceutiques, avec la possibilité d'entrer également sur le marché des pharmacies de préparation.
Genefic, Inc., eine Tochtergesellschaft von Dalrada Financial (OTCQB:DFCO), hat ein neues Videointerview mit CEO Dan Riley veröffentlicht. Das Interview hebt das signifikante Umsatzwachstum von Genefic sowie den Erfolg im Bereich der Spezialapotheken seit seiner Gründung im Oktober 2023 hervor. Riley spricht über die beeindruckende vierteljährliche Leistung des Unternehmens, wobei der Umsatz in aufeinanderfolgenden Quartalen von 4 Millionen auf 8 Millionen Dollar gestiegen ist.
Das Interview behandelt auch Genefics Expansionsstrategie, zu der zwei lizenzierte Diagnoselabore, eine in allen 50 Bundesstaaten lizenzierte Spezialapotheke und eine vor kurzem übernommene Infusionsapotheke in der Region New Orleans gehört. Riley betont das Ziel des Unternehmens, eine zentrale Anlaufstelle für alle Apothekendienstleistungen und -segmente zu werden und möglicherweise auch in den Markt für Rezepturen einzutreten.
- Revenue doubled from $4 million to $8 million in consecutive quarters
- Expansion into multiple pharmacy verticals: specialty, diagnostic, and infusion
- 50-state licensed specialty pharmacy
- Recently acquired infusion pharmacy in New Orleans area
- Potential entry into compounding pharmacy market
- None.
Dan Riley provides updates and insights about the subsidiary's success and significant revenue growth
SAN DIEGO, CA / ACCESSWIRE / July 24, 2024 / Genefic, Inc., a wholly-owned subsidiary of Dalrada Financial Corporation (OTCQB:DFCO),("Dalrada," "the Company"), announced the release of a new insightful video interview featuring CEO, Dan Riley. The in-depth interview covers important news and updates, and highlights Genefic's growth as the subsidiary continues its impressive revenue growth.
Riley's interview with SmallCapVoice also details Genefic's ongoing success in the specialty pharmacy space-a direct result of its long-term strategy and vision that was officially launched in October of 2023.
This strategy has ultimately delivered considerable traction within the subsidiary's pharmacy and laboratory division as Genefic has two licensed diagnostic laboratories, a 50-state licensed specialty pharmacy, and a recently-acquired infusion pharmacy with a physical location in the greater New Orleans area.
Watch the full interview here.
"We've been very happy and positive about the growth, quarter over quarter. With just launching in October, doing
Later in the interview, after breaking down each the pharmaceutical sectors Genefic is currently in and hinting at the potential of entering the compounding pharmacy market, Riley said, "We're really trying to cover all verticals within the pharmacy market. What that means is we'll be a one-stop shop, which is the strategy for all pharmacy services and verticals."
About Genefic
A wholly-owned subsidiary of Dalrada Financial Corporation, Genefic, Inc. proudly delivers frontline health products and services through redesigned systems and reimagined patient care. Genefic's unique pharmacy solution, Genefic Specialty Pharmacy, offers more than 30 years of dedicated expertise providing patient advocacy through end-to-end prescription services, medical education, and patient advocacy and support.
About Dalrada Financial Corporation
Dalrada Financial Corporation (OTCQB:DFCO) is a multi-national holding company that develops, manufactures, and sells a robust suite of products and services in the Clean Energy and Health Care sectors. Dalrada's core segments include Dalrada Climate Technology, which offers cutting-edge heat pump technology for industrial and residential applications, and Genefic Specialty Pharmacy, which provides end-to-end prescription services as well as patient advocacy and support.
Dalrada Financial Corporation consistently drives innovation that delivers maximum impact, bringing increased value to its shareholders.
For more information, please visit www.dalrada.com, and follow us on LinkedIn, Facebook, Twitter, and YouTube.
Forward-Looking Statements
Statements contained in this press release, other than statements of historical fact, particularly statements relating to cost reductions and the anticipated pre-tax savings from the cost reduction program, restructuring costs, footprint rationalization, simplifying and streamlining our operations, reducing complexity, enhancing the speed of decision-making, leveraging our sourcing capabilities and the timing of implementation and completion of the cost reduction program, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the beliefs and assumptions of management based on information available to us at the time such statements are made. These statements, which are generally identifiable by the use of the words "will," "believe," "expect," "intend," "anticipate," "estimate," "forecast," "project," "plan," and similar expressions, are subject to certain risks and uncertainties, are made as of the date hereof, and we undertake no duty or obligation to update them. Forward-looking statements are subject to the occurrence of many events outside the Company's control and actual results and the timing of events may differ materially from those suggested or implied by such forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the US Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K.
Media contact: Michael Eslinger (meslinger@dalrada.com)
SOURCE: Dalrada Financial Corp.
View the original press release on accesswire.com
FAQ
What is Genefic's recent quarterly revenue growth according to CEO Dan Riley?
What pharmacy verticals does Genefic (DFCO) currently operate in?
When did Genefic (DFCO) officially launch its long-term strategy in the specialty pharmacy space?
What is Genefic's (DFCO) goal in the pharmacy market according to CEO Dan Riley?
